DOCSLIB.ORG

Bioinformatics Analysis of the Target Gene of Fibroblast Growth Factor Receptor 3 in Bladder Cancer and Associated Molecular Mechanisms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioinformatics Analysis of the Target Gene of Fibroblast Growth Factor Receptor 3 in Bladder Cancer and Associated Molecular Mechanisms ONCOLOGY LETTERS 10: 543-549, 2015 Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms XING AI1*, ZHUO-MIN JIA1,2*, JUAN WANG3, GUI-PING DI1, XU ZHANG2, FENGLING SUN1, TONG ZANG1 and XIUMEI LIAO1 1Department of Urology, Military General Hospital of Beijing PLA, Beijing 100700; 2Department of Urology, Chinese PLA General Hospital, Beijing 100853; 3Department of Medicine, Military General Hospital of Beijing PLA, Beijing 100700, P.R. China Received August 4, 2014; Accepted April 24, 2015 DOI: 10.3892/ol.2015.3231 Abstract. The aim of the present study was to elucidate CCNB1 and H2AFZ were significantly associated with BC, the molecular mechanisms of fibroblast growth factor as determined by the protein-protein interaction network of receptor 3 (FGFR3) activation via overexpression or muta- DEGs and co-expressed genes. In conclusion, the present tion of the FGFR3 target gene in bladder cancer (BC). study revealed the involvement of FGFR3 in the regulation The transcription profile data GSE41035, which included of sterol biosynthesis and metabolism in the maintenance of 18 BC samples, containing 3 independent FGFR3 short BC; in addition, the present study provided a novel insight hairpin (sh)RNA, and 6 control samples, containing enhanced into the molecular mechanisms of FGFR3 in BC. These green fluorescent protein (EGFP) shRNA, were obtained results may therefore contribute to the theoretical guidance from the National Center of Biotechnology Information into the detection and therapy of BC. Gene Expression Omnibus database. The Limma package with multiple testing correction was used to identify differen- Introduction tially expressed genes (DEGs) between FGFR3 knockdown and control samples. Gene ontology (GO) and pathway Bladder cancer (BC) is estimated to be among the top five enrichment analysis were conducted in order to investigate most common types of cancer in western countries and ranks the DEGs at the functional level. In addition, differential number 13 in terms of cancer-associated mortality world- co-expression analysis was employed to construct a gene wide (1,2). Histologically, BC may be classified based on the co-expression network. A total of 196 DEGs were acquired, depth of invasion: pTa, papillary; pT1, lamina propria invasion; of which 101 were downregulated and 95 were upregulated. pT2, muscle invasive; pT3, invasion to peri-vesical fat; and pT4, In addition, a gene signature was identified linking FGFR3 locally advanced (3,4). BC results from long-term exposure to signaling with de novo sterol biosynthesis and metabolism contaminants or other environmental factors involving gene using GO and pathway enrichment analysis. Furthermore, mutations and progressive cellular damage. Parkin et al (5) the present study demonstrated that the genes NME2, demonstrated that the incidence of BC is almost four times higher in men than in women and inducing factors include tobacco smoke, prolonged exposure to chemical substances and race (6,7). Genetic mutations in gene expression may lead to the Correspondence to: Dr Zhuo-Min Jia, Department of Urology, malignant transformation of bladder cells. High-throughput Military General Hospital of Beijing PLA, 5 Nanmeng Cang Road, Dongcheng, Beijing 100700, P.R. China DNA microarray analyses have identified multiple DNA muta- E-mail: [email protected] tions and alterations in the genesis of BC; these include genes encoding for B cell lymphoma‑2, p53, H‑Ras and fibroblast Dr Xu Zhang, Department of Urology, Chinese PLA General growth factor receptor 3 (FGFR3) (8,9). FGFR3 is a tyrosine Hospital, 28 Fuxing Road, Haidian, Beijing 100853, P.R. China kinase receptor that regulates fundamental developmental E-mail: [email protected] pathways and triggers a range of cellular processes, including *Contributed equally proliferation, differentiation, migration and apoptosis (10). The FGFR3 gene is located on chromosome region 4p16.3 (11) Key words: bladder cancer, differentially expressed genes, and it is made up of 9 exons and 18 introns (12). The structure gene ontology and pathway enrichment analysis, protein-protein of FGFR3 is composed of an extracellular domain consisting interaction network, differentially co-expressed genes of two or three immunoglobulin-like domains, a hydrophobic transmembrane domain and an intracellular tyrosine kinase domain (13). Upon ligand binding, FGFR3 forms dimers 544 AI et al: THE ROLE OF FGFR3 IN BLADDER CANCER and activates the intracellular kinase domain, resulting in of all probes for a given gene were reduced to a single autophosphorylation of this domain. The phosphorylated value by taking the average expression value. Subsequently, residues are the binding targets of the adaptor proteins and missing data was imputed and quartile data normalization their binding results in the activation of several signal trans- was performed by robust multichip averaging using Affy duction pathways, including the Ras mitogen-activated protein package in R software (version 3.1; http://www.bioconductor. kinase (MAPK) signaling pathway and phosphoinositide org/packages/release/bioc/html/affy.html) (24). The Limma 3-kinase (PI3K) Akt mammalian target of rapamycin (mTOR) package version 3.24.2 (http://www.bioconductor.org/pack- pathway (14). ages/release/bioc/html/limma.html) (25) in R language with There are two mechanisms to explain the abnormal acti- multiple testing correction was then used according to the vation of FGFR3: Overexpression or activating mutations. Benjamini & Hochberg method (26) in order to identify DEGs FGFR3 mutations have been identified in multiple dwarf- between BC samples and normal controls. P<0.05 and |log(fold isms (15), such as hypochondroplasia, and in multiple types of change; FC)|>1 were defined as the thresholds. cancer, including prostate cancer (16), cervical cancer (17) and BC. FGFR3 mutations were reported in BC for the first time by Gene ontology (GO) enrichment analysis. In order to inves- Cappellen et al (18). There is evidence to suggest that codons tigate DEGs at the molecular and functional level, the online 248, 249 and 375 are the major mutation hot spots in BC (19); biological tool, Database for Annotation, Visualization and in addition, activating mutations of FGFR3 have been revealed Integrated Discovery (DAVID) version 6.7 (http://david. primarily in pTa (60-70%) and in pT1-4 (16-20%) (19). Over- abcc.Ncifcrf.gov/), was used for GO term enrichment and expression of FGFR3 has been frequently identified in BC; genes were clustered according to GO. GO is a collection furthermore, Jebar et al (20) demonstrated that the expression of controlled vocabularies, which include molecular func- of FGFR3 was higher in low stage BC. Du et al (21) identified tion, cellular component and biological process, to describe a gene pathway linking FGFR3 with sterol and lipid metabo- the biology of a gene product in any organism. P<0.05 was lism through transcriptional profiling of BC cells subjected selected as the cut-off criterion during the analysis. to short hairpin (sh)RNA knockdown of FGFR3 (21). FGFR3 has been demonstrated to be a promising therapeutic target for Pathway enrichment analysis. The theoretical principle for BC (22,23). However, the molecular mechanisms of FGFR3 enrichment analysis is that associated functional genes are activation, via overexpression or activating mutation, in BC more likely to be selected in the abnormal biological process remain to be elucidated. by the high-through screening technologies (27). Based on The present study aimed to analyze microarray data in the selected genes, researchers are able to correctly identify order to investigate the changes in gene expression profiles that the biological processes involved. In order to identify the occur following loss of FGFR3; in addition, the current study enriched pathways of DEGs, DAVID was used with P<0.05 aimed to explore the target genes and molecular mechanisms as the threshold. The pathways used as DAVID input for of FGFR3 The genes that were differentially expressed in cluster analysis were from Kyoto Encyclopedia of Genes FGFR3-deleted cell lines as compared with the control cell and Genomes (KEGG; http://www.genome.jp/kegg/) and lines were considered to be potential transcriptional targets BIOCARTA (http://www.biocarta.com/). of over-expressed FGFR3 in bladder cancer. Furthermore, a protein-protein interaction (PPI) network was constructed and PPI network construction. PPIs are crucial for all biological the disturbed biological pathways were identified following processes. In the present study, the PPI network was FGFR3 knockdown in order to explore the pathogenesis and constructed based on the Protein Interaction Network Anal- occurrence of BC associated with FGFR3. ysis platform (PINA2) database (http://cbg.garvan.unsw.edu. au/pina/). PINA2 (28) is a database containing known and Materials and methods predicted associations of protein interaction. The interactions include direct (physical) and indirect (functional) associations. Messenger RNA expression profile data of BC. The transcrip- Of note, the protein names in the Universal Protein Resource tion profile dataset of BC was obtained from National Center database (http://www.ebi.ac.uk/uniprot/remotingAPI/), which of Biotechnology Information Gene Expression Omnibus correspond to the DEGs, were submitted to construct the database (http://www.ncbi.nlm.nih.gov/geo/). The accession PPI network. Here
Load more

Recommended publications
  • 32-2709: PPIL1 Recombinant Protein Description Product Info Application
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-2709: PPIL1 Recombinant Protein Alternative Name : Peptidyl-Prolyl Cis-Trans Isomerase-Like 1,PPIL-1,CYPL1,hCyPX,MGC678,PPIase,CGI-124,PPIL1. Description Source : Escherichia Coli. PPIL1 Human Recombinant protein produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 174 amino acids (1-166) and having a molecular mass of 19.3 kDa. PPIL1 is fused to 8 amino acid His Tag at C-terminus and is purified by proprietary chromatographic techniques. PPIL1 belongs to the cyclophilin family of peptidylprolyl isomerases (PPIases). The cyclophilins are a well conserved, ubiquitous family, members of which take an significant part in protein folding, immunosuppression by cyclosporin A, and infection of HIV-1 virions. PPIL1 protein increases the folding of proteins and catalyze the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. PPIL1 is involved in proliferation of cancer cells through modulation of phosphorylation of stathmin. PPIL1 is a novel molecular target for colon- cancer therapy. Product Info Amount : 50 µg Purification : Greater than 95.0% as determined by SDS-PAGE. Content : PPIL1 solution containing 20 mM Tris-HCl buffer (pH 8.0) and 20% glycerol PPIL1 Human Recombinant although stable at 4°C for 1 week, should be stored desiccated below Storage condition : -18°C. Please prevent freeze thaw cycles. Amino Acid : MAAIPPDSWQ PPNVYLETSM GIIVLELYWK HAPKTCKNFA ELARRGYYNG TKFHRIIKDF MIQGGDPTGT GRGGASIYGK QFEDELHPDL KFTGAGILAM ANAGPDTNGS QFFVTLAPTQ WLDGKHTIFG RVCQGIGMVN RVGMVETNSQ DRPVDDVKII KAYPSGLEHH HHHH. Application Note Specific activity is > 300 nmoles/min/mg, and is defined as the amount of enzyme that cleaves 1umole of suc-AAFP-pNA per minute at 25C in Tris-Hcl pH8.0 using chymotrypsin.
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • In This Table Protein Name, Uniprot Code, Gene Name P-Value
    Supplementary Table S1: In this table protein name, uniprot code, gene name p-value and Fold change (FC) for each comparison are shown, for 299 of the 301 significantly regulated proteins found in both comparisons (p-value<0.01, fold change (FC) >+/-0.37) ALS versus control and FTLD-U versus control. Two uncharacterized proteins have been excluded from this list Protein name Uniprot Gene name p value FC FTLD-U p value FC ALS FTLD-U ALS Cytochrome b-c1 complex P14927 UQCRB 1.534E-03 -1.591E+00 6.005E-04 -1.639E+00 subunit 7 NADH dehydrogenase O95182 NDUFA7 4.127E-04 -9.471E-01 3.467E-05 -1.643E+00 [ubiquinone] 1 alpha subcomplex subunit 7 NADH dehydrogenase O43678 NDUFA2 3.230E-04 -9.145E-01 2.113E-04 -1.450E+00 [ubiquinone] 1 alpha subcomplex subunit 2 NADH dehydrogenase O43920 NDUFS5 1.769E-04 -8.829E-01 3.235E-05 -1.007E+00 [ubiquinone] iron-sulfur protein 5 ARF GTPase-activating A0A0C4DGN6 GIT1 1.306E-03 -8.810E-01 1.115E-03 -7.228E-01 protein GIT1 Methylglutaconyl-CoA Q13825 AUH 6.097E-04 -7.666E-01 5.619E-06 -1.178E+00 hydratase, mitochondrial ADP/ATP translocase 1 P12235 SLC25A4 6.068E-03 -6.095E-01 3.595E-04 -1.011E+00 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 Protein kinase C and casein Q9BY11 PACSIN1 3.837E-03 -5.863E-01 3.680E-06 -1.824E+00 kinase substrate in neurons protein 1 Tubulin polymerization- O94811 TPPP 6.466E-03 -5.755E-01 6.943E-06 -1.169E+00 promoting protein MIC C9JRZ6 CHCHD3 2.912E-02 -6.187E-01 2.195E-03 -9.781E-01 Mitochondrial 2-
    [Show full text]
  • The Genetic Architecture of Secretory PLA2 (Spla2) Genes and Their Impact on Spla2 Activity/Mass and Association with CHD Risk
    The Genetic Architecture of Secretory PLA2 (sPLA2) Genes and their Impact on sPLA2 Activity/Mass and Association with CHD Risk Holly Jane Exeter University College London A thesis submitted in accordance with the regulations of the University College London for the degree of Doctor of Philosophy Centre for Cardiovascular Genetics UCL Institute of Cardiovascular Science 1 For Mum and Dad 2 Declaration I, Holly Jane Exeter confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. In relation to specific chapters I would like to clarify my role: In Chapter 3 I was responsible for identifying SNPs of interest from the results of previously genotyped studies. I was then responsible for the in depth literature and bioinformatics study undertaken for PLA2G2A, sPLA2-IIA and the SNPs of interest. I designed the primers for all cloning and EMSA work and carried out all of the cloning experiments, luciferase assays, TaqMan Gene Expression assays and EMSAs according to the methods described. I also carried out the statistical work relating to the luciferase assay experiments. In Chapter 4 I was responsible for genotyping 2 of the studies in the final meta-analysis; IMPROVE and CYPRUS. I used the PRISMA guidelines to compile an in depth literature search of the sPLA2 inhibitor, varespladib. I was part of the core group of investigators who met to discuss the results and direction of the study (participants of the MR study are at the end of the thesis).
    [Show full text]
  • Datasheet: VMA00345KT Product Details
    Datasheet: VMA00345KT Description: NUCLEOSIDE DIPHOSPHATE KINASE A ANTIBODY WITH CONTROL LYSATE Specificity: NUCLEOSIDE DIPHOSPHATE KINASE A Format: Purified Product Type: PrecisionAb™ Monoclonal Isotype: IgG2b Quantity: 2 Westerns Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Mouse, Rat Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation 20μl Mouse monoclonal antibody prepared by affinity chromatography on Protein G Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen Recombinant human nucleoside diphosphate kinase A External Database Links UniProt: P15531 Related reagents Entrez Gene: 4830 NME1 Related reagents Synonyms NDPKA, NM23 Page 1 of 3 Specificity Mouse anti Human nucleoside diphosphate kinase A antibody recognizes nucleoside diphosphate kinase A, also known as NDP kinase A, granzyme A-activated DNase, metastasis inhibition factor nm23, non-metastatic cells 1 and tumor metastatic process-associated protein. The NME1 gene was identified because of its reduced mRNA transcript levels in highly metastatic cells.
    [Show full text]
  • Frontiers Medicine Csa 2021
    1 Frontiers Medicine 2 February 3, 2021 3 Title: Cyclosporin A: a repurposable drug in the treatment of COVID-19 ? 4 5 Running title: Cyclosporin A and COVID-19 6 7 Christian A. DEVAUX,1,2*, Cléa MELENOTTE1, Marie-Dominique 8 PIERCECCHI-MARTI3,4, Clémence DELTEIL3,4, and Didier RAOULT1 9 10 1Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, 11 France 12 2 CNRS, Marseille, France 13 3 Department of Legal Medicine, Hôpital de la Timone, Marseille University Hospital 14 Center, Marseille, France 15 4 Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France 16 17 *Corresponding author : 18 Christian Devaux, PhD 19 IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385 Marseille, France 20 Phone: (+33) 4 13 73 20 51 21 Fax : (+33) 4 13 73 20 52 22 E-mail: [email protected] 23 24 Abstract length: 190 words; Manuscript length:,7817 words 25 Figures: 7 26 Table 4 27 Keywords: SARS-CoV-2; COVID-19; Cyclosporin A; Cyclophilin; ACE2 28 Summary: 29 COVID-19 is now at the forefront of major health challenge faced globally, creating an urgent 30 need for safe and efficient therapeutic strategies. Given the high attrition rates, high costs and 31 quite slow development of drug discovery, repurposing of known FDA-approved molecules is 32 increasingly becoming an attractive issue in order to quickly find molecules capable of 33 preventing and/or curing COVID-19 patients. Cyclosporin A (CsA), a common anti-rejection 34 drug widely used in transplantation, has recently been shown to exhibit substantial anti- 35 SARS-CoV-2 antiviral activity and anti-COVID-19 effect.
    [Show full text]
  • Global Screening of Sentrin-Specific Protease Family Substrates in Sumoylation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.25.964072; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Global Screening of Sentrin-Specific Protease Family Substrates in SUMOylation Yunzhi Wang, 1, 4 Xiaohui Wu,1, 4 Rui Ge,1, 4 Lei Song, 2 Kai Li, 2 Sha Tian,1 Lili Cai, 1 Mingwei Liu, 2 Wenhao Shi, 2Guoying Yu, 3 Bei Zhen, 2 Yi Wang, 2 Fuchu He, 1, 2, * Jun Qin, 1, 2, * Chen Ding1, 2, * 1State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Zhongshan Hospital, Fudan University, Shanghai, 200432, China 2State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, 102206, China 3State Key Laboratory of Cell Differentiation and Regulation, College of Life Science, Henan Normal University, Xinxiang, Henan 453007 4Co-first author *Correspondence: [email protected] (C.D.); [email protected] (J.Q.); [email protected] (F.H.); Key Words 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.25.964072; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Posttranslational modification; SUMO; Sentrin/SUMO-specific proteases; Mass Spectrometry; Innate Immunity Abstract Post-translational modification of proteins by the addition of small ubiquitin-related modifier (SUMO) is a dynamic process, in which deSUMOylation is carried out by members of the Sentrin/SUMO-specific protease (SENP) family.
    [Show full text]
  • Identi Cation of Crucial Genes in Metastatic Osteosarcoma And
    Identication of crucial genes in metastatic osteosarcoma and prognostic biomarker in osteosarcoma patients Weihao Wang First Aliated Hospital of Shantou University Medical College Zhaoyong Liu First Aliated Hospital of Shantou University Medical College Weiqing Lu First Aliated Hospital of Shantou University Medical College Huancheng Guo First Aliated Hospital of Shantou University Medical College Chunbin Zhou First Aliated Hospital of Shantou University Medical College Youbin Lin First Aliated Hospital of Shantou University Medical College Hu Wang ( [email protected] ) the First Aliated Hospital of Shantou University Medical Collegethe First Aliated Hospital of Shantou University Medical Collegethe First Aliated Hospital of Shantou University Medical Collegethe First Aliated Hospital of Shantou University Med Research article Keywords: osteosarcoma, metastasis, crucial genes, prognostic biomarker Posted Date: July 22nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-44119/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract Background Osteosarcoma is still a challenging cancer that poses a huge threat to human health worldwide, especially in young people. The aim of this study was to identify prognostic genes associated with neoplasm metastasis in osteosarcoma, and construct a prognostic nomogram to help the orthopedist to assess prognosis of osteosarcoma patients. Methods Gene expression and clinical information were extracted from the TARGET database. Differentially expressed genes (DEGs) associated with osteosarcoma metastasis were identied and subjected to GO functional and KEGG pathway enrichment analyses. Survival and Cox analyses were used to identify prognostic genes. Results First, 214 DEGs were identied as crucial genes associated with osteosarcoma metastasis.
    [Show full text]
  • Transcriptome Analysis of Paralichthys Olivaceus Erythrocytes Reveals Profound Immune Responses Induced by Edwardsiella Tarda Infection
    International Journal of Molecular Sciences Article Transcriptome Analysis of Paralichthys olivaceus Erythrocytes Reveals Profound Immune Responses Induced by Edwardsiella tarda Infection Bin Sun 1,2,3 , Xuepeng Li 1, Xianhui Ning 1 and Li Sun 1,2,* 1 CAS Key Laboratory of Experimental Marine Biology, CAS Center for Ocean Mega-Science, Institute of Oceanology, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China; [email protected] (B.S.); [email protected] (X.L.); [email protected] (X.N.) 2 Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, 1 Wenhai Road, Qingdao 266237, China 3 University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China * Correspondence: [email protected]; Tel.: +86-532-82898829 Received: 13 March 2020; Accepted: 3 April 2020; Published: 28 April 2020 Abstract: Unlike mammalian red blood cells (RBCs), fish RBCs are nucleated and thus capable of gene expression. Japanese flounder (Paralichthys olivaceus) is a species of marine fish with important economic values. Flounder are susceptible to Edwardsiella tarda, a severe bacterial pathogen that is able to infect and survive in flounder phagocytes. However, the infectivity of and the immune response induced by E. tarda in flounder RBCs are unclear. In the present research, we found that E. tarda was able to invade and replicate inside flounder RBCs in both in vitro and in vivo infections. To investigate the immune response induced by E. tarda in RBCs, transcriptome analysis of the spleen RBCs of flounder challenged with E. tarda was performed. Six sequencing libraries were constructed, and an average of 43 million clean reads per library were obtained, with 85% of the reads being successfully mapped to the genome of flounder.
    [Show full text]
  • Immunosuppression by Cyclosporine Cyclophilin A-Deficient Mice Are
    Cyclophilin A-Deficient Mice Are Resistant to Immunosuppression by Cyclosporine John Colgan, Mohammed Asmal, Bin Yu and Jeremy Luban This information is current as J Immunol 2005; 174:6030-6038; ; of October 2, 2021. doi: 10.4049/jimmunol.174.10.6030 http://www.jimmunol.org/content/174/10/6030 References This article cites 53 articles, 28 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/174/10/6030.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 2, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Cyclophilin A-Deficient Mice Are Resistant to Immunosuppression by Cyclosporine1 John Colgan,2* Mohammed Asmal,* Bin Yu,* and Jeremy Luban3*† Cyclosporine is an immunosuppressive drug that is widely used to prevent organ transplant rejection. Known intracellular ligands for cyclosporine include the cyclophilins, a large family of phylogenetically conserved proteins that potentially regulate protein folding in cells.
    [Show full text]
  • Structural and Functional Insights Into Human Nuclear Cyclophilins
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 November 2018 doi:10.20944/preprints201811.0037.v1 Peer-reviewed version available at Biomolecules 2018, 8, 161; doi:10.3390/biom8040161 1 Review 2 Structural and Functional Insights into Human 3 Nuclear Cyclophilins 4 Caroline Rajiv12 and Tara L. Davis13,* 5 1 Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, 6 Philadelphia PA USA 19102. 7 2 Janssen Pharmaceuticals, Inc., 22-21062, 1400 McKean Rd, Spring House, PA 19477; 8 [email protected] 9 3 FORMA Therapeutics, 550 Arsenal St. Ste. 100, Boston, MA 02472; [email protected] 10 11 * Correspondence: [email protected]; Tel.: +01-857-209-2342 12 13 Abstract: The peptidyl-prolyl isomerases of the cyclophilin type are distributed throughout human 14 cells, including eight found solely in the nucleus. Nuclear cyclophilins are involved in complexes 15 that regulate chromatin modification, transcription, and pre-mRNA splicing. This review collects 16 what is known about the eight human nuclear cyclophilins: PPIH, PPIE, PPIL1, PPIL2, PPIL3, PPIG, 17 CWC27, and PPWD1. Each “spliceophilin” is evaluated in relation to the spliceosomal complex in 18 which it has been studied, and current work studying the biological roles of these cyclophilins in 19 the nucleus are discussed. The eight human splicing complexes available in the RCSB are analyzed 20 from the viewpoint of the human spliceophilins. Future directions in structural and cellular biology, 21 and the importance of developing spliceophilin-specific inhibitors, are considered. 22 23 Keywords: Peptidyl-prolyl isomerases; nuclear cyclophilins; spliceophilins; alternative splicing; 24 spliceosomes; NMR; x-ray crystallography 25 26 27 1.
    [Show full text]
  • RNA-Seq and GSEA Identifies Suppression of Ligand-Gated
    www.nature.com/scientificreports OPEN RNA‑seq and GSEA identifes suppression of ligand‑gated chloride efux channels as the major gene pathway contributing to form deprivation myopia Loretta Giummarra Vocale1,4*, Sheila Crewther1, Nina Riddell1, Nathan E. Hall1,2, Melanie Murphy1 & David Crewther1,3 Currently there is no consensus regarding the aetiology of the excessive ocular volume that characterizes high myopia. Thus, we aimed to test whether the gene pathways identifed by gene set enrichment analysis of RNA‑seq transcriptomics refutes the predictions of the Retinal Ion Driven Efux (RIDE) hypothesis when applied to the induction of form‑deprivation myopia (FDM) and subsequent recovery (post‑occluder removal). We found that the induction of profound FDM led to signifcant suppression in the ligand‑gated chloride ion channel transport pathway via suppression of glycine, GABAA and GABAC ionotropic receptors. Post‑occluder removal for short term recovery from FDM of 6 h and 24 h, induced signifcant upregulation of the gene families linked to cone receptor phototransduction, mitochondrial energy, and complement pathways. These fndings support a model of form deprivation myopia as a Cl− ion driven adaptive fuid response to the modulation of the visual signal cascade by form deprivation that in turn afects the resultant ionic environment of the outer and inner retinal tissues, axial and vitreal elongation as predicted by the RIDE model. Occluder removal and return to normal light conditions led to return to more normal upregulation of phototransduction, slowed growth rate, refractive recovery and apparent return towards physiological homeostasis. Myopia (short-sightedness) is the most common visual disorder worldwide and the greatest risk factor for severe ophthalmic diseases in older individuals especially those with high (-5D) refractive errors1.
    [Show full text]